Proteomic profiling identifies specific histone species associated with leukemic and cancer cells

Clinical Proteomics
Rajbir SinghMark R Parthun

Abstract

Chromatin is an extraordinarily complex structure. Much of this complexity results from the presence of numerous histone post-translational modifications and histone variants. Alterations in the patterns of histone post-translational modifications are emerging as a feature of many types of cancer and have been shown to have prognostic value. We have applied a liquid chromatography/mass spectrometry-based approach to comprehensively characterize the histone proteome in primary samples from chronic lymphocytic leukemia (CLL) patients, as well as bladder and breast cancer cell culture models. When compared to non-malignant CD19+ B cells from healthy donors, the CLL histone proteome showed a distinct signature of differentially expressed species, spanning all the histones studied and including both post-translationally modified species and unmodified, non-allelic replication-dependent histone isoforms. However, the large changes in histone H3 and H4 that are characteristic of many cancer types were not observed. One of species of H2A (mass = 14,063 Da) was the most strongly associated with time to treatment in CLL patients. CLL patient samples also demonstrated histone profiles that were distinct from those of the bladder and breas...Continue Reading

References

Dec 15, 1996·Experimental Cell Research·O WittD Doenecke
Mar 4, 1999·Biological Chemistry·W AlbigD Doenecke
Mar 23, 2001·Breast Cancer Research and Treatment·S J SantnerF R Miller
Jan 7, 2005·Nature·Jens S AndersenMatthias Mann
Jul 1, 2005·Nature·David B SeligsonSiavash K Kurdistani
Feb 21, 2007·Methods : a Companion to Methods in Enzymology·Amy R KnappMark R Parthun
Oct 2, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fabrice BarlésiJose Antonio Rodriguez
Apr 8, 2009·The American Journal of Pathology·David B SeligsonSiavash K Kurdistani
Sep 10, 2009·The Prostate·Jörg EllingerAlexander von Ruecker
Feb 18, 2010·International Journal of Cancer. Journal International Du Cancer·Jörg EllingerAlexander von Ruecker
Jul 14, 2011·Proteomics·Jia YouMichael A Freitas
Dec 14, 2011·Cancer Investigation·Jörg EllingerSebastian Rogenhofer
Mar 15, 2012·BMC Urology·Turang E BehbahaniJörg Ellinger
Jan 26, 2013·Current Opinion in Cell Biology·Tanja Waldmann, Robert Schneider
May 17, 2013·Journal of Proteome Research·Kelly H TeluAmir Mortazavi

❮ Previous
Next ❯

Citations

Jul 5, 2016·Analytical Chemistry·Bram HeijsLiam A McDonnell
Jan 13, 2017·Journal of Proteome Research·Gisele F A PicchiLyris M F de Godoy
Aug 5, 2020·Epigenetics & Chromatin·Sanket G ShahSanjay Gupta
Oct 20, 2017·Epigenetics & Chromatin·Saikat BhattacharyaSanjay Gupta
Dec 23, 2016·Expert Review of Proteomics·Paula DíezManuel Fuentes
Jul 3, 2018·Journal of Controlled Release : Official Journal of the Controlled Release Society·Matthew D ChristensenKaushal Rege
Mar 27, 2021·The Journal of Physical Chemistry. B·Daniel EspirituAnna R Panchenko
Jul 25, 2021·Cancers·Dimitra MavridouMichalis Aivaliotis

❮ Previous
Next ❯

Methods Mentioned

BETA
acetylation
X-ray

Software Mentioned

AmaZon
MassLynx
SAS

Related Concepts

Related Feeds

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Cell Signaling & Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. This feed covers the latest research on signaling and epigenetics in cell growth and cancer.

Cancer Epigenetics & Methyl-CpG (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. Here is the latest research on cancer epigenetics and methyl-CpG binding proteins including ZBTB38.

Cancer Epigenetics

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Bladder Carcinoma In Situ

Bladder Carcinoma In Situ is a superficial bladder cancer that occurs on the surface layer of the bladder. Discover the latest research on this precancerous condition in this feed.

Cancer -Omics

A variety of different high-throughput technologies can be used to identify the complete catalog of changes that characterize the molecular profile of cohorts of tumor samples. Discover the latest insights gained from cancer 'omics' in this feed.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

Cancer Epigenetics and Chromatin (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin and its role in cancer epigenetics please follow this feed to learn more.

Cancer Epigenetics (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. Here is the latest research on cancer epigenetics.

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Cancer Epigenetics Chromatin Complexes (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on chromatin complexes and their role in cancer epigenetics.

Acute Myeloid Leukaemia & RNA

Acute myeloid leukaemia (AML) is a common hematological type of cancer. As the population ages, there has been a rise in the frequency of AML. RNA expression has been used to see if there are different genetic profiles that exist within AML and whether these may underpin the variations in survival rates. Here is the latest research on AML and RNA.